

BioLines Weekender

To Our New Jersey Life Sciences Community:

Welcome to the *Weekender*.

It's hard to believe that we are entering the first weekend in December, which means a lot of activity on the business front - securing the last few product approvals, closing the books on some important deals - and bringing in the holidays.



No doubt it's been a busy first week of December for New Jersey's expanding life sciences industry, with plenty of stories making their way down the pipeline. A total of 28 biotech companies were on the list of 44 companies identified by the New Jersey Economic Development Authority (EDA) as sharing a total of \$54 million under the State's Technology Business Tax Certificate Transfer Program. NPS Pharma announced that the European Medicines Agency (EMA) has validated and initiated its review of the company's marketing authorization application (MAA) for Natpar (known as Natpara in the US) for the treatment of Hypoparathyroidism. Levolta Pharmaceuticals posted Phase II results for patients with Osteoarthritis at the American College of Rheumatology Annual Meeting, while ADMA Biologics announced positive Phase III data for Primary Immune Deficiency Disease (PIDD) patients. Arno Therapeutics officially named a full-time CEO and the BASF Corporation gave NJ schools a \$100K STEM grant, helping further the study of science for kids in grades K-12.

At the institutional level, Rowan University was certainly busy. The Rowan Innovation Venture Fund appointed a new Managing Director and Dr. Mark Byrne was named the new head of the Biomedical Engineering program.

So find some time this busy weekend to catch up on all the news by reading the *Weekender*.

Because Patients Can't Wait!

The BioNJ Team

Highlights include:

- **BioNJ Calendar** - The BioNJ and LES-NJ Chapter Gala Holiday Celebration will take place on December 15 at the Madison Hotel in Morristown, NJ. The BioNJ Annual Dinner Meeting will be held on February 5 at the Hilton East Brunswick in East Brunswick, NJ. Registration is open for both events.
- **BioNJ News** - BioNJ and Choose New Jersey have reserved space at the BIO 2015 International Convention in Philadelphia. Stop by and see what BioNJ has to offer. Reserve your housing for BIO 2015.
- **NJ Industry News** - 28 biotech companies among 44 emerging companies approved to share funding available through New Jersey's NOL program. Levolta Pharmaceuticals presents Phase II study results for potential osteoarthritis therapy. New study from Germany on photodynamic diagnosis using flexible scopes. NPS Pharma's Teduglutide granted orphan drug designation in Japan. BASF gives NJ schools \$100K STEM grant. Pharma manufacturer renews lease. Lexicon announces completion of \$280 million in financing

transactions. Google Development Group of North Jersey to host Google Solve for X Event. Implementing hexaminolevulinate HCL blue light cystoscopy. Amicus Therapeutics prices underwritten offering of common stock. Agile Therapeutics announces publication of data on low-dose investigational contraceptive patch. European Medicines Agency validates marketing authorization application for Natpar (known as Natpara in the US) in hypoparathyroidism. ADMA Biologics announces positive top-line Phase III data for primary immune deficiency disease (PIDD) patients. Immunomedics announces outcome of 2014 Annual Meeting of Stockholders. CannaPharmaRx officially opens headquarters in New Jersey. PTC Therapeutics announces launch of Translarna (ataluren) in Germany. Cancer Genetics Inc. announces the appointments of Dr. Howard McLeod and Geoffrey Harris to its board. Bergen County-based medtech company secures capital from EDA to fuel growth. Celldex Therapeutics initiates a Phase II study of Glembatumumab Vedotin in patients with advanced Melanoma. Flemington drug company Arno Therapeutics gives interim CEO the job.

- **Advocacy for Innovation, Brought to You by Celgene** - MY LIFE IS WORTH IT calls for balanced view of the value of advanced therapeutics for cancer patients.
- **NJ University/Institution News** - Rowan researchers get travelers on the road. Rowan Innovation Venture Fund appoints technology and investment leader as Managing Director. Rowan University appoints Dr. Mark Byrne to head new Biomedical Engineering program.
- **Purchasing Consortium** - See What Our Members are Saving on Lab Supplies Alone! UPS is Collecting and Delivering Wishes.
- **Talent News** - Check out the latest jobs from our Talent Network.
- **BioNJ Tweets of the Week** - Featuring tweets by FDA Drug Info and *Wall Street Journal* medical writer Ron Winslow.

BioNJ Calendar

BioNJ and LES-NJ Chapter Gala Holiday Celebration

December 15, 2014
Madison Hotel
Morristown, NJ

[Register Now](#)

BioNJ Annual Dinner Meeting

February 5, 2015
Hilton East Brunswick
East Brunswick, NJ

[Register Now](#)

BioNJ News

Reserve Your Exhibit Space and Hotel for BIO 2015

BioNJ and Choose New Jersey have reserved premium space on the BIO 2015 International Convention trade show floor! We are working to incorporate the New Jersey Story into our pavilion and want to see how we might include you!

Also, don't get left without a room at the biggest industry event of the year! With 44 percent of the housing space already reserved, rooms are promising to be in short supply very soon. Make sure you're at the world's largest biotechnology meeting by [RESERVING YOUR ROOM TODAY.](#)

INTERESTED IN LEARNING MORE ABOUT THE NEW JERSEY PAVILION?

Please contact Debbie Mennito at BioNJ by phone at [609-890-3185](tel:609-890-3185) or by e-mail at DMennito@BioNJ.org.

NJ Industry News

Make sure to send us your stories via BioNJ@BioNJ.org.

28 Biotech Companies Among 44 Emerging Companies Approved to Share Funding Available through New Jersey's NOL Program

Furthering the Christie Administration's commitment to cultivating the growth of emerging tech and biotech businesses in the Garden State, the New Jersey Economic Development Authority (EDA) on December 3 announced that 44 companies were approved to share a total of \$54 million available through the State's Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2015. Of the 44 emerging companies, 28 were identified as biotech companies.

Conceived of and advocated for by BioNJ in 1999, this competitive program enables companies to sell New Jersey tax losses and/or research and development tax credits to raise cash to finance their growth and operations.

Please [click here](#) to read the full press release.

Levolta Pharmaceuticals Presents Phase II Study Results for Potential Osteoarthritis Therapy at ACR Annual Meeting

Levolta Pharmaceuticals, Inc. announced on November 18 the results of an exploratory Phase II study for a potential disease modifying drug for patients with knee osteoarthritis (OA) at the 2014 American College of Rheumatology Annual Meeting in Boston.

Please [click here](#) to read the full press release.

New Study from Germany on Photodynamic Diagnosis Using Flexible Scopes

Princeton-based BioNJ Member Photocure shared a new published study showing that Flexible PDD using the chip-on-the-tip technology was feasible with an excellent fluorescence quality.

Sensitivity and specificity of Flexible PDD was equivalent to the current gold standard - the rigid blue light endoscopy.

Please [click here](#) to read the full article.

Teduglutide Granted Orphan Drug Designation in Japan

BioNJ Member NPS Pharma, headquartered in Bedminster, announced on November 24 that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Teduglutide orphan drug designation for the treatment of Short Bowel Syndrome (SBS). Also, due to the strong medical need for SBS treatments in Japan, the MHLW's expert committee on Unapproved New Drugs and New Indications with High Medical Needs requested that NPS Pharma Japan K.K. develop Teduglutide for adult SBS earlier this year.

Please [click here](#) to read the full press release.

BASF Gives NJ Schools \$100K STEM Grant

BASF Corporation donated \$100,000 to support science education programs in 20 schools throughout New Jersey. The BASF Science Education Grants, each totaling \$5,000, will enhance science, technology, engineering and math (STEM) related learning for students in grades K - 12, according to *New Jersey Business Magazine*.

Please [click here](#) to read the full article.

Pharma Manufacturer Renews Lease

Pharmaceutical manufacturer Kyorin U.S.A. Inc., a subsidiary of Toyko-based Kyorin Pharmaceutical Co. Ltd., has renewed its 2,370-square-foot lease at the Glenpointe Center West in Teaneck.

Please [click here](#) to read the full article.

Lexicon Announces Completion of \$280 Million In Financing Transactions

Lexicon Pharmaceuticals, Inc. announced on November 26 the completion of previously announced concurrent financing transactions, resulting in gross proceeds of \$280 million.

Please [click here](#) to read the full press release.

Google Development Group of North Jersey to Host Google Solve for X Event

The Google Development Group of North Jersey has been selected as one of two locations in the nation, and one of 12 locations worldwide, for Google's Solve for X event. Solve for X is a global initiative from Google aimed to find pioneers in science and technology.

Please [click here](#) to read the full article.

Implementing Hexaminolevulinate HCL Blue Light Cystoscopy: A Nursing Perspective

Princeton-based BioNJ Member Photocure shared a nursing perspective on successful implementation of blue-light cystoscopy published in the *AORN Journal*.

Please [click here](#) to read the full article.

Amicus Therapeutics Prices Underwritten Offering of Common Stock

Amicus Therapeutics, headquartered in Cranbury and a BioNJ Member, announced on November 18 the pricing of an underwritten offering of 13,850,000 shares of its common stock at \$6.50 per share.

Please [click here](#) here to read the full press release.

Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch

Agile Therapeutics, Inc., a Princeton-based BioNJ Member, announced on December 1 the publication of two manuscripts containing data from a Phase III clinical trial of Twirla (AG200-15), an investigational, once-weekly contraceptive patch.

Please [click here](#) to read the full press release.

European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA) in Hypoparathyroidism

Bedminster Township BioNJ Member NPS Pharma announced on December 2 that the European Medicines Agency (EMA) has validated and initiated its review of the company's marketing authorization application (MAA) for Natpar (known as Natpara in the US) (parathyroid hormone (rDNA) for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH).

Please [click here](#) to read the full press release.

ADMA Biologics Announces Positive Top-Line Phase III Data For Primary Immune Deficiency Disease (PID) Patients

Ramsey-based BioNJ Member ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced on December 3 its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.

Please [click here](#) to read the full press release.

Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders

BioNJ Member Immunomedics, Inc., located in Morris Plains, announced on December 3 that stockholders of the Company have approved all the matters submitted to them at the Company's Annual Meeting of Stockholders.

Please [click here](#) to read the full press release.

CannaPharmaRx, Inc. Officially Opens Headquarters in New Jersey

CannaPharmaRx, Inc., the New Jersey-based pharmaceutical research and discovery company, officially took possession of its new headquarters in Carney's Point Township in southwest New Jersey.

Please [click here](#) to read the full press release.

PTC Therapeutics Announces Launch of Translarna(TM) (ataluren) in Germany

South Plainfield-based BioNJ Member PTC Therapeutics, Inc. announced on December 3 that Translarna (ataluren) is now commercially available to patients in Germany, the first country to launch in the European Union (EU), with first shipments expected to begin this week.

Please [click here](#) to read the full press release.

Cancer Genetics Inc. Announces the Appointments of Dr. Howard McLeod and Geoffrey Harris to Its Board of Directors

Cancer Genetics, Inc., a BioNJ Member located in Rutherford, announced on December 3 the addition of Howard McLeod, Pharm. D., and Geoffrey Harris to the Company's Board of Directors.

Please [click here](#) to read the full press release.

Bergen County-Based Medtech Company Secures Capital From EDA to Fuel Growth

The New Jersey Economic Development Authority (EDA) announced on December 4 that it has closed on a \$1 million loan to support Bergen County-based Ivy Sports Medicine.

Please [click here](#) to read the full press release.

Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced Melanoma

Hampton-based BioNJ Member Celldex Therapeutics, Inc. announced on December 4 that it has initiated an open-label Phase II study of Glabatumumab Vedotin (CDX-011) in patients with unresectable Stage III or IV melanoma.

Please [click here](#) to read the full press release.

Flemington Drug Company Gives Interim CEO The Job

Flemington-based cancer drug company Arno Therapeutics Inc. has given its interim CEO, Dr. Alexander Zukiwski, the job on a permanent basis, the company announced on December 4.

Please [click here](#) to read the full article.

Advocacy for Innovation

Brought to You by Celgene Corporation.

MY LIFE IS WORTH IT Calls for Balanced View of the Value of Advanced Therapeutics for Cancer Patients at Global Hematology Conference

MY LIFE IS WORTH IT, an online patient-focused initiative, says treatment decisions should be based on benefit to the patient, not price.

Please [click here](#) to read the full press release.

NJ University/Institution News

Rowan University Appoints Dr. Mark Byrne to Head New Biomedical Engineering Program

BioNJ Member Rowan University, located in Glassboro, has named educator and researcher Dr. Mark Byrne as professor and inaugural chairman of the new Biomedical Engineering Department in its nationally recognized College of Engineering.

Please [click here](#) to read the full article.

From Here to There: Rowan Researchers Get Travelers on The Road

Rowan University and its College of Engineering professors and students are figuratively and literally taking their research to the road, helping to make travelers' journeys - and the environments in which they are taken - safer.

Please [click here](#) to read the full article.

Rowan Innovation Venture Fund Appoints Technology and Investment Leader as Managing Director

The Rowan Innovation Venture Fund, LLC, housed by the Rowan University Foundation, appointed technology leader Howard Lubert as managing director, bringing the Fund one step closer to accepting applications for its first investments.

Please [click here](#) to read the full article.

Purchasing Consortium

Growing biotechnology companies face a unique set of business issues. See the Member savings generated In 2012 on Fisher Lab supplies alone!

What money are you leaving on the table?

The estimated average savings in 2012 for all BioNJ Members participating in the savings program is 39%.

Small Biotech Company (<10 Researchers)
Estimated Lab Supply Spend at List: \$18,025
BioNJ Member Pricing: \$10,529
Estimated Savings: \$7,496 or 41%

Mid-Size Biotech Company (10-20 Researchers)
Estimated Lab Supply Spend at List: \$687,539
BioNJ Member Pricing: \$415,891
Estimated Savings: \$271,648 or 39.5%

Large Biotech Company (>20 Researchers)
Estimated Lab Supply Spend at List: \$2,915,646
BioNJ Member Pricing: \$1,842,979
Estimated Savings: \$1,072,667 or 36.7%

Take advantage of your Member Benefits and save even more with the full offering of discounts from office supplies to shipping and executive liability to IT services!

Please [click here](#) to see available Member Benefits.

Taking A Survey Could Win You Starbucks!

BioNJ is currently conducting a survey on your office purchasing habits. We have pushed back our submission date to Monday, December 8. Your participation could earn you a Starbucks gift card!

Please [click here](#) to take the survey.

BioNJ Talent Network

Job Leads

BioNJ can help you find the perfect candidate for your open positions. Call us today!

Please [click here](#) to view all the job postings on the LSTN at BioNJ website.

BioNJ Tweets of the Week

- @FDA_Drug_Info tweeted, "[FDA approves new drug for #polycythemia vera, a chronic type of bone marrow disease: http://go.usa.gov/6NJQ](http://go.usa.gov/6NJQ)"
- @ronwinslow tweeted, "[Cancer's super-survivors: How immunotherapy is transforming oncology -- my story http://on.wsj.com/1vIW08Y](http://on.wsj.com/1vIW08Y)"

Please contact BioNJ at BioNJ@BioNJ.org
or [609-890-3185](tel:609-890-3185) with any questions.

Connect with us: